Global Markets for Diabetes Therapeutics and Diagnostics
Description
Global Markets for Diabetes Therapeutics and Diagnostics
Report Scope:
This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.
Report Includes:
162 data tables and 63 additional tables
An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca
Table of Contents
336 Pages
- Chapter 1 Introduction
- Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Report
- Scope of Report
- Information Sources
- Methodology
- Secondary Research
- Primary Interviews
- Geographic Breakdown
- Chapter 2 Summary and Highlights
- Market Overview
- Significant Developments and Trends
- Chapter 3 Market Overview
- What is Diabetes?
- Types of Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes Mellitus (GDM) or Hyperglycemia in Pregnancy
- Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG)
- Epidemiology of Diabetes
- Gender Distribution
- Regional Disparities
- Market Factors Driving the Growth and Development of the Market
- Market Drivers
- Market Restraints
- Chapter 4 Global Market for Diabetes Therapeutics
- Overview
- Classification and Types of Antidiabetic Medications
- Injectable Therapies for Diabetes
- Oral Antidiabetic Drugs (OADs)
- Facing the Patent Cliff
- Latest Technological Advances, Developments and Product Pipelines for Diabetic Medications
- Current Product Pipeline
- Other Potential Therapies Currently Under Investigation
- Chapter 5 Global Market for Diabetes Monitoring Devices and Accessories
- Overview
- Self-Monitoring of Blood Glucose (SMBG)
- SMBG Market Structure
- Latest Technological Advances and Developments in Blood Glucose Devices
- Continuous Glucose Monitoring (CGM) Systems
- Development of CGM Systems
- Chapter 6 Global Market for Diabetes Delivery Devices by Type
- Overview
- Insulin Syringes
- Advantages of Using Insulin Syringes
- Disadvantages of Using Insulin Syringes
- Latest Technological Advances and Developments in Insulin Syringes
- Insulin Delivery Pen Devices
- Disposable Insulin Pens
- Reusable Insulin Pens
- Latest Technological Advances and Developments in Insulin Delivery Pen Devices
- Insulin Jet Injectors
- Advantages of Using Insulin Jet Injectors
- Disadvantages of Using Insulin Jet Injectors
- External Insulin Pumps
- Advantages of Insulin Pumps
- Disadvantages of Insulin Pumps
- Latest Technological Advances and Developments in Insulin Pump Systems
- Implantable Insulin Pumps
- Closed-Loop Artificial Pancreas
- Bionic Pancreas
- Artificial Pancreas (the Physiological Approach)
- Insulin Inhalers
- Advantages of Insulin Inhalers
- Disadvantages of Insulin Inhalers
- Types of Insulin Inhalers
- Insulin Patches
- Oral Insulin Delivery
- Chapter 7 Global Market for Diabetes Therapeutics and Diagnostics by End User
- Overview
- Hospitals and Clinics
- Diagnostic Centers
- Home Care Organizations
- Chapter 8 Global Market for Diabetes Therapeutics and Diagnostics by Region
- Overview
- North America
- United States
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Rest of the World
- South America
- Middle East and Africa
- Chapter 9 Sustainability in the Market for Diabetes Therapeutics and Diagnostics: An ESG Perspective
- Introduction
- Market for Diabetes Therapeutics and Diagnostics: ESG Performance Analysis
- Chapter 10 Emerging Technologies
- Patient Outcomes Beyond Glucose Control
- Diabetes Technology with Digital Health
- Growing Trend Toward Oral Antidiabetics
- Growing Focus on Accessibility and Affordability of Medicine
- Artificial Pancreas
- Chapter 11 M&As and Venture Funding Outlook in the Market
- M&A Analysis
- Lilly's Acquisition of Protomer Technologies
- Chapter 12 Competitive Landscape
- Recent Strategic Initiatives, By Major Players in The Market
- Chapter 13 Company Profiles
- 77 ELEKTRONIKA KFT.
- ABBOTT
- ALTUCELL
- ASCENSIA DIABETES CARE HOLDINGS AG.
- ASTRAZENECA
- B. BRAUN SE
- BIOCON
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- DANAHER
- DEXCOM INC.
- EMBECTA CORP.
- INSULET CORPORATION.
- JOHNSON & JOHNSON SERVICES INC.
- LIFESCAN IP HOLDINGS LLC
- LILLY
- MEDTRONIC
- MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
- MERCK & CO. INC.
- MERCK KGAA
- NEXTCELL PHARMA AB
- NIPRO
- NOVA BIOMEDICAL
- NOVARTIS AG
- NOVO NORDISK A/S
- ROCHE (F. HOFFMANN-LA ROCHE LTD)
- SANOFI
- TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- TANDEM DIABETES CARE INC.
- TERUMO CORPORATION
- YPSOMED AG
- Chapter 14 Appendix
- Government Regulatory Agencies and Professional Organizations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
